Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

   Recruiting · Phase 1, Phase 2 · Immunoglobulin Light Chain (AL) Amyloidosis

   NCT06158854 · AbbVie Inc. · 13 U.S. investigators

   $655,061research payments

2. [Trial of device that is not approved or cleared by the U.S. FDA]

   Withheld

   NCT07215247 · AbbVie Inc. · 23 U.S. investigators

   $654,878research payments

3. Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

   Recruiting · Phase 2 · Mantle Cell Lymphoma

   NCT06263491 · Lilly USA, LLC · 1 U.S. investigator

   $654,039research payments

4. A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography

   Completed · Phase 3 · Rheumatoid Arthritis

   NCT00767325 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

   $653,905research payments

5. A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

   Recruiting · Phase 3 · Primary Open Angle Glaucoma

   NCT06822738 · AbbVie Inc. · 18 U.S. investigators

   $653,687research payments

6. A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

   Completed · Phase 3 · Ulcerative Colitis

   NCT05767021 · Eli Lilly and Company · 41 U.S. investigators

   $652,370research payments

7. A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

   Completed · Phase 1, Phase 2 · SARS-CoV-2

   NCT05827926 · ModernaTX, Inc. · 30 U.S. investigators

   $650,072research payments

8. Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

   Completed · Phase 3 · Presbyopia

   NCT06542497 · Oyster Point Pharma, Inc. · 28 U.S. investigators

   $649,297research payments

9. Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

   Completed · Phase 3 · Open-Angle Glaucoma

   NCT03891446 · AbbVie Inc. · 33 U.S. investigators

   $648,472research payments

10. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

    Recruiting · Phase 2 · Ovarian Cancer

    NCT06787612 · Regeneron Pharmaceuticals, Inc. · 8 U.S. investigators

    $647,337research payments

11. MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

    Active, not recruiting · Not applicable · Intracranial Aneurysm

    NCT05409989 · Microvention, Inc. · 25 U.S. investigators

    $644,547research payments

12. A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

    Recruiting · Phase 3 · Chronic Migraine

    NCT06810505 · AbbVie Inc. · 30 U.S. investigators

    $643,739research payments

13. Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

    Terminated · Heart Failure

    NCT04502316 · Cvrx, Inc. · 48 U.S. investigators

    $643,265research payments

14. A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    Recruiting · Phase 1, Phase 2 · Healthy Volunteers

    NCT05648214 · Regeneron Pharmaceuticals, Inc. · 7 U.S. investigators

    $641,806research payments

15. Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

    Completed · Phase 3 · Lymphoma, Non-Hodgkin

    NCT01996865 · E.r. Squibb & Sons, L.l.c. · 53 U.S. investigators

    $641,646research payments

16. A Study of LY3437943 in Participants With Impaired and Normal Liver Function

    Completed · Phase 1 · Healthy

    NCT05916560 · Eli Lilly and Company · 4 U.S. investigators

    $639,487research payments

17. Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

    Recruiting · Phase 3 · Breast Reconstruction

    NCT06575192 · AbbVie Inc. · 19 U.S. investigators

    $631,071research payments

18. A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

    Active, not recruiting · Phase 1, Phase 2 · Non-small Cell Lung Cancer

    NCT06644768 · Daiichi Sankyo Inc. · 8 U.S. investigators

    $630,558research payments

19. BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

    Active, not recruiting · Phase 2 · Transplant Rejection

    NCT05156710 · Sanofi US Services Inc. · 7 U.S. investigators

    $629,747research payments

20. Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

    Terminated · Not applicable · Diabetic Foot Ulcer

    NCT06572839 · Royal Biologics, Inc. · 10 U.S. investigators

    $627,676research payments

21. A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

    Active, not recruiting · Phase 3 · Psoriatic Arthritis

    NCT03675308 · AbbVie Inc. · 20 U.S. investigators

    $626,987research payments

22. Tracking Results of Ablations to Combat AF Registry Generation 2

    Recruiting · Atrial Fibrillation

    NCT05111015 · Atricure, Inc. · 18 U.S. investigators

    $624,877research payments

23. LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

    Completed · Not applicable · Heart Failure

    NCT04790344 · Boston Scientific Corporation · 60 U.S. investigators

    $624,430research payments

24. POA Retrospective Repository

    Status unknown · Oncology

    NCT03326479 · Caris Mpi, Inc. · 6 U.S. investigators

    $623,345research payments

25. A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

    Completed · Phase 3 · Inherited Mitochondrial Disease

    NCT05218655 · Ptc Therapeutics, Inc. · 14 U.S. investigators

    $622,478research payments

26. Obsidio™ Conformable Embolic Registry

    Completed · Hypervascular Tumors

    NCT06170619 · Boston Scientific Corporation · 20 U.S. investigators

    $621,856research payments

27. A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

    Active, not recruiting · Phase 2 · Resectable Non-small Cell Lung Cancer

    NCT06161441 · Regeneron Pharmaceuticals, Inc. · 11 U.S. investigators

    $617,073research payments

28. Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

    Completed · Phase 4 · Genital Psoriasis

    NCT05969223 · AbbVie Inc. · 31 U.S. investigators

    $616,862research payments

29. A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

    Active, not recruiting · Phase 3 · Fabry Disease

    NCT05280548 · Genzyme Corporation · 7 U.S. investigators

    $616,033research payments

30. A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

    Completed · Phase 1 · Respiratory Syncytial Virus

    NCT04528719 · ModernaTX, Inc. · 24 U.S. investigators

    $614,483research payments

31. A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

    Completed · Phase 3 · Follicular Lymphoma

    NCT01650701 · E.r. Squibb & Sons, L.l.c. · 16 U.S. investigators

    $614,370research payments

32. A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

    Active, not recruiting · Phase 3 · Mantle Cell Lymphoma

    NCT04002297 · Beone Medicines Ltd. · 14 U.S. investigators

    $613,931research payments

33. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

    Recruiting · Phase 4 · Chronic Lymphocytic Leukemia

    NCT06876662 · Eli Lilly and Company · 14 U.S. investigators

    $613,771research payments

34. A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

    Recruiting · Phase 2 · Metastatic Colorectal Cancer

    NCT06820463 · AbbVie Inc. · 17 U.S. investigators

    $613,587research payments

35. Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

    Terminated · Phase 1, Phase 2 · Cancer

    NCT04717375 · Sanofi US Services Inc. · 8 U.S. investigators

    $612,277research payments

36. Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

    Active, not recruiting · Phase 2 · Type 1 Diabetes Mellitus

    NCT06111586 · Genzyme Corporation · 14 U.S. investigators

    $606,485research payments

37. Phase 2b Open-Label Repeat Kidney Biopsy Study

    Active, not recruiting · Phase 2 · IgA Nephropathy

    NCT06740526 · Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 U.S. investigators

    $605,407research payments

38. A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

    Recruiting · Phase 3 · Relapsed/Refractory Follicular Lymphoma

    NCT06149286 · Regeneron Pharmaceuticals, Inc. · 7 U.S. investigators

    $605,384research payments

39. A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

    Active, not recruiting · Phase 2 · Sjogren Disease

    NCT06928142 · Otsuka Pharmaceutical Development & Commercialization, Inc. · 17 U.S. investigators

    $603,863research payments

40. Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

    Recruiting · Phase 2 · Rhabdomyosarcoma

    NCT06023641 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $603,778research payments

41. Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

    Recruiting · Phase 3 · Ovarian Cancer

    NCT06819007 · Daiichi Sankyo Inc. · 17 U.S. investigators

    $603,497research payments

42. Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

    Completed · Phase 2 · Influenza, Human

    NCT05874713 · Seqirus USA Inc · 9 U.S. investigators

    $599,829research payments

43. Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program

    Active, not recruiting · Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

    NCT04632953 · Ultragenyx Pharmaceutical Inc. · 13 U.S. investigators

    $599,732research payments

44. Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

    Terminated · Phase 2 · Atopic Dermatitis

    NCT06058156 · Sanofi US Services Inc. · 9 U.S. investigators

    $595,795research payments

45. Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

    Active, not recruiting · Phase 3 · Gaucher's Disease Type III

    NCT05222906 · Sanofi US Services Inc. · 4 U.S. investigators

    $595,612research payments

46. A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

    Recruiting · Phase 4 · Ulcerative Colitis

    NCT06581328 · Takeda Pharmaceuticals U.S.A., Inc. · 33 U.S. investigators

    $593,541research payments

47. Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

    Active, not recruiting · Heart Failure

    NCT03970343 · Impulse Dynamics (USA) Inc. · 74 U.S. investigators

    $592,961research payments

48. Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

    Completed · Phase 3 · Partial Lipodystrophy

    NCT05164341 · Chiesi USA, Inc. · 12 U.S. investigators

    $591,275research payments

49. SUBLOCADE Long-term Outcomes

    Completed · Opioid Use Disorder

    NCT05860959 · Indivior Inc. · 30 U.S. investigators

    $590,190research payments

50. Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

    Active, not recruiting · Phase 2 · Urothelial Carcinoma

    NCT06632951 · AbbVie Inc. · 14 U.S. investigators

    $588,801research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.